INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
- U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine
- INOVIO to report on interim U.S. Phase 1 clinical trial results in late June
- INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer
finance.yahoo.com/news/inovio-receives-71-million-contract-113000799.html
Inovio gets $71 million from U.S. defense dept for COVID-19 vaccine device
Inovio Pharmaceuticals Inc said on Tuesday it has received $71 million from the U.S. Department of Defense (DoD) to scale up production of the company's devices that are used to administer its experimental COVID-19 vaccine into the skin.
Inovio, which began human testing of its vaccine in April, said it expects to report interim results from the trial later this month, and added that it would begin mid-stage trials this summer.
There are currently no approved vaccines for COVID-19, the disease caused by the novel coronavirus, with governments, drugmakers and researchers working on about 100 vaccine programs.
finance.yahoo.com/news/inovio-gets-71-million-u-114513281.html
It also said as part of this agreement that the DoD plans to buy an undisclosed number of the devices.
The vaccine candidate is currently being tested in a Phase 1 clinical trial; interim results from that study are expected to be released this month.
marketwatch.com/story/inovio-shares-jump-on-government-funding-for-vaccine-device-2020-06-23?siteid=yhoof2
The U.S. Food and Drug Administration cleared the vaccine for testing in April.
INO-4800 targets the major surface antigen protein that causes covid-19. And the Phase I trial showed that vaccination generated robust binding and neutralizing antibody as well as T-cell responses in animals.
Phase I clinical studies of the vaccine will be available next month and a Phase II/III efficacy trial is planned for July or August, the company said.
thestreet.com/investing/inovio-shares-up-as-pentagon-funds-vaccine-delivery-device?puc=yahoo&cm_ven=YAHOO
realmoney.thestreet.com/investing/stocks/inovio-pharmaceuticals-is-breaking-out-on-the-upside-here-s-our-strategy-15355567?puc=yahoo&cm_ven=YAHOO
- U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine
- INOVIO to report on interim U.S. Phase 1 clinical trial results in late June
- INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer
finance.yahoo.com/news/inovio-receives-71-million-contract-113000799.html
Inovio gets $71 million from U.S. defense dept for COVID-19 vaccine device
Inovio Pharmaceuticals Inc said on Tuesday it has received $71 million from the U.S. Department of Defense (DoD) to scale up production of the company's devices that are used to administer its experimental COVID-19 vaccine into the skin.
Inovio, which began human testing of its vaccine in April, said it expects to report interim results from the trial later this month, and added that it would begin mid-stage trials this summer.
There are currently no approved vaccines for COVID-19, the disease caused by the novel coronavirus, with governments, drugmakers and researchers working on about 100 vaccine programs.
finance.yahoo.com/news/inovio-gets-71-million-u-114513281.html
It also said as part of this agreement that the DoD plans to buy an undisclosed number of the devices.
The vaccine candidate is currently being tested in a Phase 1 clinical trial; interim results from that study are expected to be released this month.
marketwatch.com/story/inovio-shares-jump-on-government-funding-for-vaccine-device-2020-06-23?siteid=yhoof2
The U.S. Food and Drug Administration cleared the vaccine for testing in April.
INO-4800 targets the major surface antigen protein that causes covid-19. And the Phase I trial showed that vaccination generated robust binding and neutralizing antibody as well as T-cell responses in animals.
Phase I clinical studies of the vaccine will be available next month and a Phase II/III efficacy trial is planned for July or August, the company said.
thestreet.com/investing/inovio-shares-up-as-pentagon-funds-vaccine-delivery-device?puc=yahoo&cm_ven=YAHOO
realmoney.thestreet.com/investing/stocks/inovio-pharmaceuticals-is-breaking-out-on-the-upside-here-s-our-strategy-15355567?puc=yahoo&cm_ven=YAHOO
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.